Scarica l'app Stockscreener
94.40
0.82%
-0.78
Dopo l'orario di chiusura:
94.30
-0.10
-0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$95.18
Aprire:
$94.77
Volume 24 ore:
8.30M
Relative Volume:
0.64
Capitalizzazione di mercato:
$164.43B
Reddito:
$45.13B
Utile/perdita netta:
$6.28B
Rapporto P/E:
26.30
EPS:
3.5895
Flusso di cassa netto:
$7.38B
1 W Prestazione:
-1.05%
1M Prestazione:
+3.45%
6M Prestazione:
-25.03%
1 anno Prestazione:
-29.14%
Intervallo 1D:
$93.91
$94.98
Intervallo di 1 settimana:
$92.99
$98.14
Portata 52W:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
94.40 | 165.79B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
327.11 | 125.30B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
82.39 | 104.98B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.99 | 66.60B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
91.33 | 53.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Schiff launches inquiry into DOJ's closure of probe into Abbott Labs over bacterial contamination at baby formula plant - CBS News
Abbott Laboratories stock stays supported by diversified health-care business - AD HOC NEWS
Abbott Laboratories stock may move 4.5% on earnings release - Investing.com
Abbott Laboratories highlights diagnostics and medical devices as investors assess long-term growth - AD HOC NEWS
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott Laboratories (ABT) Q1 Sales And Guidance Put Fair Value Back In Focus - Yahoo Finance
Abbott Laboratories balances diagnostics demand and investor expectations - Ad-hoc-news.de
Is Abbott Laboratories (ABT) Stock Still a Healthcare Growth Opportunity After Analyst Target Cut? - Insider Monkey
FreeStyle Libre 3 Sensor from Abbott Laboratoriesdiscreet glucose tracking for active diabetes pa - AD HOC NEWS
Is Abbott Laboratories (ABT) Undervalued After Its Glucose Monitoring Growth Narrative? - simplywall.st
Abbott (ABT) Has a Multi-Platform Device-and-Diagnostics Engine Bigger Than the Libre Narrative - AlphaStreet
Trump Admin Stopped Criminal Charges Against Abbott Nutrition for Infant Formula Illnesses - Food Safety Magazine
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Abbott Laboratories (ABT) Stock Analysis: A Healthcare Giant with a 22.35% Upside Potential - DirectorsTalk Interviews
DOJ Closing Abbott Labs Case Spurs Wider Corporate Crime Retreat - Bloomberg Law News
Abbott Laboratories Stock (ABT) Opinions on Recent FDA Approvals and Product Launches - Quiver Quantitative
ABT Stock Quote Price and Forecast - CNN
Abbott Labs must face lawsuit over PediaSure children's growth claims - MSN
Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering - Seeking Alpha
Abbott Laboratories (NYSE:ABT) Passes the Caviar Cruise Quality Screen with Strong Growth and Profitability - ChartMill
Is Index Shuffle And Probe Shift Reshaping The Investment Case For Abbott Laboratories (ABT)? - simplywall.st
DOJ ends investigation into infant formula company linked to deadly cronobacter outbreak - foodsafetynews.com
Abbott Laboratories (ABT) Shares Surge 3.5% -- What GF Score of 80 Tells Investors - GuruFocus
Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula - Reuters
Trump Loaded Up on Abbott Laboratories Stock Before His DOJ Dropped Criminal Probe - Common Dreams
A Mom Said Infant Formula Killed Her Baby. The Manufacturer Closed the File. - KFF Health News
Abbott Laboratories (NYSE: ABT) director receives 432 stock equivalent units as deferred fees - Stock Titan
Abbott Laboratories (ABT) director granted 416 stock equivalent units as board fees - Stock Titan
Abbott (ABT) director receives 363 stock equivalent units as board compensation - Stock Titan
Abbott (ABT) director Kevin Conroy receives 231 stock equivalent units as fees - Stock Titan
Form 4 Abbott Laboratories For: 1 July By Investing.com - Investing.com Canada
Abbott Laboratories (ABT) director receives 347 stock equivalent units as board compensation - Stock Titan
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott (NYSE: ABT) EVP withholds 269 shares to satisfy tax obligations - Stock Titan
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott (ABT) Clears A Major Legal Risk As DOJ Ends Criminal Formula Probe - Yahoo Finance
Has Abbott Laboratories (ABT) Fallen Too Far Below Fair Value? - simplywall.st
Baird starts Abbott at Outperform, sees product pipeline driving growth - Yahoo Finance
Baird starts Abbott at Outperform, sees product pipeline driving growth By Investing.com - Investing.com Canada
Abbott Laboratories (ABT) Receives Outperform Rating from Baird with $121 Target - GuruFocus
Abbott Laboratories highlights diversified healthcare portfolio as a long-term driver - AD HOC NEWS
Abbott gains as Baird issues new outperform on growth outlook - MSN
Abbott stock gains as Baird issues new Outperform (ABT:NYSE) - Seeking Alpha
Baird initiates Abbott stock coverage with Outperform rating - Investing.com
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX, and More - Yahoo Finance
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
US criminal probe into Abbott infant-formula plant closed - Global Food Industry News
Abbott Laboratories earnings calendar, shares in focus on the NYSE - AD HOC NEWS
Enterprise value to EBIT forward of Abbott Laboratories Pakistan Limited – PSX:ABOT - TradingView
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
2.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):